Gilead Sciences, Inc. Boosts Its Full-Year Outlook Thanks to Stronger-Than-Expected Hep C Sales
When Gilead Sciences, Inc. (NASDAQ: GILD) reported its first-quarter results earlier this year, everyone expected sales for the biotech's hepatitis C franchise to be way down. Those expectations were met in spades. The primary good news was that Gilead's HIV drug sales were up, although not nearly enough to offset the hep C decline.
Gilead provided an update on its second-quarter performance after the market closed on Wednesday. Again, expectations were for lower hep C sales. There were some hopes, though, that the rate of decline would at least slow, and that Gilead's HIV drugs would pick up momentum. Here are the highlights of what actually happened during the second quarter.
Image source: Getty Images.
Source: Fool.com
Gilead Sciences Inc Stock
€70.94
0.440%
We see a rather positive sentiment for Gilead Sciences Inc with 11 Buy predictions and 1 Sell predictions.
With a target price of 85 € there is a slightly positive potential of 19.82% for Gilead Sciences Inc compared to the current price of 70.94 €.
